Holen Sie sich die Stockscreener-App
1.90
0.52%
-0.01
Handel nachbörslich:
1.93
0.03
+1.58%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt DRRX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$1.91
Offen:
$1.88
24-Stunden-Volumen:
447.09K
Relative Volume:
0.47
Marktkapitalisierung:
$58.98M
Einnahmen:
$8.59M
Nettoeinkommen (Verlust:
$-17.07M
KGV:
-3.1148
EPS:
-0.61
Netto-Cashflow:
$-21.90M
1W Leistung:
+2.15%
1M Leistung:
+203.66%
6M Leistung:
+153.37%
1J Leistung:
+34.75%
1-Tages-Spanne:
$1.87
$1.91
1-Wochen-Bereich:
$1.85
$1.92
52-Wochen-Spanne:
$0.4801
$2.64
Durect Corp Stock (DRRX) Company Profile
Firmenname
Durect Corp
Sektor
Telefon
(408) 777-1417
Adresse
10240 BUBB ROAD, CUPERTINO, CA
Vergleichen Sie DRRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DRRX
Durect Corp
|
1.90 | 58.05M | 8.59M | -17.07M | -21.90M | -0.61 |
|
ZTS
Zoetis Inc
|
152.44 | 66.04B | 9.39B | 2.61B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.77 | 45.57B | 29.98B | 958.27M | 5.31B | 0.2964 |
|
HLN
Haleon Plc Adr
|
9.69 | 42.50B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.21 | 18.84B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
309.72 | 13.59B | 2.99B | 1.21B | 1.13B | 25.06 |
Durect Corp Stock (DRRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-10-30 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-10-12 | Eingeleitet | ROTH Capital | Buy |
| 2020-07-31 | Eingeleitet | Oppenheimer | Outperform |
| 2020-01-31 | Eingeleitet | B. Riley FBR | Buy |
| 2019-11-18 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2019-09-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-03-06 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2017-10-20 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2017-10-20 | Bestätigt | Laidlaw | Buy |
| 2017-10-20 | Herabstufung | Stifel | Buy → Hold |
| 2017-07-12 | Hochstufung | Stifel | Hold → Buy |
| 2017-02-28 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-04-25 | Eingeleitet | Rodman & Renshaw | Buy |
| 2015-05-01 | Bestätigt | Cantor Fitzgerald | Buy |
| 2015-05-01 | Bestätigt | Stifel | Buy |
| 2013-03-25 | Eingeleitet | Stifel | Buy |
| 2012-11-01 | Herabstufung | C.K. Cooper | Buy → Hold |
| 2012-08-17 | Eingeleitet | C.K. Cooper | Buy |
| 2009-06-23 | Eingeleitet | Caris & Company | Buy |
| 2009-03-26 | Eingeleitet | Wedbush Morgan | Hold |
Alle ansehen
Durect Corp Aktie (DRRX) Neueste Nachrichten
DURECT Corporation Reversal Rally May Surprise BearsQuarterly Market Summary & Short-Term Trading Opportunity Alerts - 선데이타임즈
Will DURECT Corporation continue its uptrendQuarterly Market Review & Verified Entry Point Signals - Newser
Sentiment analysis tools applied to DURECT Corporation2025 Volatility Report & Growth-Oriented Investment Plans - Newser
Durect: Q2 Earnings Snapshot - Connecticut Post
Can swing trading help recover from DURECT Corporation losses [Portfolio Profit Report]Weekly Top Gainers Trade List - Newser
Published on: 2025-08-12 20:28:09 - Newser
Using economic indicators to assess DURECT Corporation potentialJuly 2025 Fed Impact & Weekly High Return Stock Forecasts - Newser
Durect (DRRX) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
DURECT (DRRX) Reports Q2 2025 Results, Press Release Attached | DRRX SEC FilingForm 8-K - Stock Titan
Biotech DURECT Gets $63M Buyout Offer from Bausch Health with $350M Future Payment Potential - Stock Titan
Market reaction to DURECT Corporation’s recent newsMomentum-Based Prediction for Quick Returns - Newser
Why DURECT Corporation stock attracts strong analyst attentionPredictive Analytics for Equity Growth Potential - Newser
Technical signs of recovery in DURECT CorporationTechnical Insight Guide for Safer Trades - Newser
How is DRRX performing? - AInvest
Is DURECT Corporation reversing from oversold territoryFree Daily Top Performing Stock Insights - Newser
Using data tools to time your DURECT Corporation exitEquity Performance Forecast Based on AI Models - Newser
Reversal indicators forming on DURECT Corporation stockPortfolio Update Report & Expert Curated Trade Ideas - Newser
DURECT (DRRX) Projected to Post Quarterly Earnings on Tuesday - Defense World
Signal strength of DURECT Corporation stock in tech scannersReal-Time Entry Forecast with Accuracy Metrics - Newser
Bausch Health to Acquire DURECT Corporation in $63M Deal to Advance Liver Disease Treatment - Insider Monkey
Durect Extends Tender Offer Deadline in Merger with Bausch Health. - AInvest
Using R and stats models for DURECT Corporation forecastingAlpha Generation Strategy with Low Volatility - Newser
Visualizing DURECT Corporation stock with heatmapsDay Trading Plan with Entry Risk Management - Newser
What is DURECT Corporation company’s growth strategyFree Investment Community - Jammu Links News
Can volume confirm reversal in DURECT CorporationSmart Forecast Signals from AI Models - Newser
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NSC, SNV, DRRX, PNFP on Behalf of Shareholders - Eastern Progress
What makes DURECT Corporation stock price move sharplyRisk/Reward Optimization Entry Point Analysis - Newser
Does DURECT Corporation show high probability of reboundMarket Correction Proof Stock Screening Analysis - Newser
Bausch Health files SC TO-C ahead of tender offer for DURECT (DRRX) | DRRX SEC FilingForm SC TO-C - Stock Titan
Bausch Health expands liver disease portfolio with DURECT Corp buy - The Pharma Letter
Can swing trading help recover from DURECT Corporation lossesSwing Watchlist With Tight Stop Placement - Newser
What does recent volatility data suggest for DURECT CorporationLow Risk High Confidence Watchlist Builder - Newser
Bausch Health to acquire liver drug developer Durect for $1.75 per share - MSN
Durect Corp: Analyzing DRRX Stock Trends - investchronicle.com
Specificity Inc. (OTCID: SPTY) AI-Powered Technology Poised to Disrupt the Media Sector – More Stocks Inside - FinancialContent
Bausch Health Adds Late-Stage Ready Alcohol Liver Disease Drug Candidate In $63 Million DURECT Buyout - inkl
Crude Oil Gains Over 1%; UnitedHealth Earnings Miss Views - Benzinga
Bausch Health to buy Durect for $63M upfront; Fulcrum’s Ph1b sickle cell data - Endpoints News
US Stocks Mixed; Procter & Gamble Posts Upbeat Earnings - Benzinga
Bausch Health stock rises, Durect flies after acquisition deal By Investing.com - Investing.com Canada
Bausch Health stock rises, Durect flies after acquisition deal - Investing.com
DRRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of DURECT Corporation Is Fair to Shareholders - Business Wire
Durect stock rises on M&A deal with Bausch Health (BHC:NYSE) - Seeking Alpha
DRRX to be acquired by Bausch for $1.75 cash + CVR worth up to $350M | DRRX SEC FilingForm 8-K - Stock Titan
Bausch Health To Acquire DURECT; Expanding Liver Disease Pipeline With Larsucosterol - Nasdaq
Bausch Health to acquire DURECT in $63 million deal for liver disease drug - Investing.com Canada
Bausch Health to acquire DURECT for $63 million upfront By Investing.com - Investing.com Canada
Bausch Health to launch tender offer for DURECT; Schedule TO-C filed | DRRX SEC FilingForm SC TO-C - Stock Titan
Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease - PR Newswire
When is the best time to exit AA Mission Acquisition Corp.Free Community Shared Smart Money Signals - Newser
Is ICF International Inc. stock overhyped or has real potentialFree Low Risk Buy Zone Opportunity Watch - Newser
Finanzdaten der Durect Corp-Aktie (DRRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.37%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):